Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Spanyolország3. fázis

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

A legfontosabb adatok

Ki végzi
Takeda
Hol
Alicante, Barcelona, Madrid és Santiago de Compostela (Spanyolország)Mind a 4 helyszín megnézéseMég 6 másik országban, 37 helyszínen
Azonosító
Állapot
Toboroz
Fázis
3. fázis
Résztvevők
210 fő, tervezett
Kezdés
2025. dec. 4.
Várható befejezés
2034. júl. 3.
A vizsgálat típusa
Beavatkozással járó, 4 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Zasocitinib
  • Placebo
A regiszteradat frissítve
2026. november 16.

Ki vehet részt

Életkor
4 év – 17 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 18 feltétel megnézéseKevesebb

Ki vehet részt

  • Participant has a diagnosis of chronic plaque psoriasis for greater than or equal to (>=) 6 months prior to the screening visit
  • Participant has stable plaque psoriasis defined as no significant flare or change in morphology (as assessed by the investigator) in psoriasis for >=6 months before screening
  • Participant has moderate-to-severe plaque psoriasis as defined by a Psoriasis Area and Severity Index (PASI) score >=12 and a Static Physician's Global Assessment (sPGA) score >=3 at screening and Day 1
  • Participant has plaque psoriasis covering >=10 percent (%) of total body surface area (BSA) at screening and Day 1
  • Participant must be a candidate for phototherapy or systemic therapy
  • Inclusion Criteria for Part A Cohort 1: The participant is male or female and aged 12 to less than (<) 18 years, at the time of screening and informed consent
  • Inclusion Criteria for Part A Cohort 2 and for Part B: The participant is male or female and aged 4 to <12 years, inclusive
  • Inclusion Criteria for Part A Cohort 1: The participant must weigh >=40 kilograms (kg) at the time of screening

Ki nem vehet részt

  • Participant has evidence of nonplaque psoriasis (erythrodermic, pustular, predominantly guttate psoriasis, predominantly inverse, or drug-induced psoriasis). If a participant meets criteria for inclusion based on typical plaque psoriasis presentation, a limited amount of inverse psoriasis is not exclusionary
  • Participant has concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the trial assessments
  • Participant has any previous exposure to zasocitinib (also known as TAK-279 or NDI-034858) or other TYK2 inhibitors or participated in any trial that included a tyrosine kinase 2 (TYK2) inhibitor, unless participant has documentation of posttrial unblinding that confirms the participant did not receive a TYK2 inhibitor
  • Participant requires systemic treatment, other than nonsteroidal anti-inflammatory drugs (NSAIDs), during the trial period for an immune-related disease
  • Participant has history of active TB infection, regardless of treatment status and has signs or symptoms of active TB or evidence of latent tuberculosis infection (LTBI)
  • Participant has active herpes virus infection, including herpes zoster or herpes simplex 1 and 2 or a history of serious herpetic infection
  • Participant has a history of chronic or recurrent bacterial disease
  • Participant has a history of opportunistic infections (for example, Pneumocystis jirovecii pneumonia, histoplasmosis, coccidiomycosis)
  • Participant has any clinically significant medical condition, evidence of an unstable clinical condition or vital signs/physical examination/laboratory/ECG abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with interpretation of trial results
  • Participant is not up to date on all required vaccinations according to current immunization guidelines as noted by country-specific pediatric authorities; Other protocol-defined inclusion/exclusion criteria apply

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 4 és 17 év között vagy?

Helyszínek itt: Spanyolország

Még 6 másik országban, 37 helyszínen

  • Hospital General Universitario Dr. BalmisAlicante, SpanyolországRésztvevőt keres
  • Hospital de la Santa Creu i Sant PauBarcelona, SpanyolországRésztvevőt keres
  • Hospital Universitario 12 de OctubreMadrid, SpanyolországRésztvevőt keres
  • Complexo Hospitalario Universitario De SantiagoSantiago de Compostela, SpanyolországRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

The main aim of this study is to see how well the medicine zasocitinib works, how safe it is, and how children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis respond to it.

A teljes eredeti leírásKevesebb

The study will be done in 2 parts: Part A will include both children and teenagers, while part B will only include children.

At first, only teenagers who meet the study rules can participate in this study. Children may only start to participate in Part A Cohort 2 once enough information has been collected from Part B to determine the appropriate dose.

Participants in Part A will initially be assigned to receive either zasocitinib or placebo for the first 16 weeks of treatment, then all participants will receive zasocitinib through the end of the study. All participants in Part B will be assigned to receive treatment with zasocitinib throughout the study.

Participants will be in the study for up to 4 years and 2 months (217 weeks), including up to 35 days for the screening period, 208 weeks of treatment (Part A and Part B) and a 4-week safety follow-up period. During the study, participants will visit their study site multiple times.

A vizsgálat 4 csoportja

  • Part A (Cohort 1): Zasocitinib (Dose A)A vizsgált kezelés

    Participants (Adolescent) aged 12 to less than (\<)18 years will receive zasocitinib Dose A once daily (QD), orally, from Week 1 to Week 16 during the double-blind placebo-controlled period followed by zasocitinib, from Week 16 to Week 208 during the open-label period.

    Kezelés: Zasocitinib

  • Part A (Cohort 2): Zasocitinib (Multiple Doses)A vizsgált kezelés

    Participants (Children) aged 4 to \<12 years will receive zasocitinib, orally, doses based on weight, from Week 1 to Week 16 during the double-blind placebo-controlled period followed by zasocitinib from Week 16 to Week 208 during the open-label period.

    Kezelés: Zasocitinib

  • Part A (Cohort 1 and Cohort 2): PlaceboPlacebo, összehasonlításként

    Participants in Cohort 1 (Adolescent aged 12 to \<18 years) and Cohort 2 (Children aged 4 to \<12 years) will receive zasocitinib matching placebo QD from Week 1 to Week 16 during the double-blind placebo-controlled period.

    Kezelés: Placebo

  • Part B: Zasocitinib (Multiple Doses)A vizsgált kezelés

    Participants (Children) aged 4 to \<12 years will receive zasocitinib, orally, doses based on weight, from Week 1 to Week 208 during the open-label period.

    Kezelés: Zasocitinib

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Zasocitinib in Pediatric Participants Aged 4 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis
Kérdések a feltételekről
Forrás: NCT07250802: ki vehet részt
A regiszteradat frissítve
2026. november 16.